Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function

Patricia A. Shi, Erika Choi, Narendranath R. Chintagari, Julia Nguyen, Xinhua Guo, Karina Yazdanbakhsh, Narla Mohandas, Abdu I. Alayash, Elizabeth A. Manci, John D. Belcher, Gregory M. Vercellotti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

There is growing evidence that extracellular haemoglobin and haem mediate inflammatory and oxidative damage in sickle cell disease. Haptoglobin (Hp), the scavenger for free haemoglobin, is depleted in most patients with sickle cell disease due to chronic haemolysis. Although single infusions of Hp can ameliorate vaso-occlusion in mouse models of sickle cell disease, prior studies have not examined the therapeutic benefits of more chronic Hp dosing on sickle cell disease manifestations. In the present study, we explored the effect of Hp treatment over a 3-month period in sickle mice at two dosing regimens: the first at a moderate dose of 200 mg/kg thrice weekly and the second at a higher dose of 400 mg/kg thrice weekly. We found that only the higher dosing regimen resulted in increased haem-oxygenase-1 and heavy chain ferritin (H-ferritin) expression and decreased iron deposition in the kidney. Despite the decreased kidney iron deposition following Hp treatment, there was no significant improvement in kidney function. However, there was a nearly significant trend towards decreased liver infarction.

Original languageEnglish (US)
Pages (from-to)714-723
Number of pages10
JournalBritish Journal of Haematology
Volume175
Issue number4
DOIs
StatePublished - Nov 1 2016

Fingerprint

Apoferritins
Haptoglobins
Sickle Cell Anemia
Iron
Kidney
Hemoglobins
Therapeutics
Heme Oxygenase (Decyclizing)
Hemolysis
Heme
Infarction
Liver

Keywords

  • H-ferritin
  • free haemoglobin
  • haem-oxygenase-1
  • haptoglobin
  • sickle cell disease

Cite this

Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. / Shi, Patricia A.; Choi, Erika; Chintagari, Narendranath R.; Nguyen, Julia; Guo, Xinhua; Yazdanbakhsh, Karina; Mohandas, Narla; Alayash, Abdu I.; Manci, Elizabeth A.; Belcher, John D.; Vercellotti, Gregory M.

In: British Journal of Haematology, Vol. 175, No. 4, 01.11.2016, p. 714-723.

Research output: Contribution to journalArticle

Shi, Patricia A. ; Choi, Erika ; Chintagari, Narendranath R. ; Nguyen, Julia ; Guo, Xinhua ; Yazdanbakhsh, Karina ; Mohandas, Narla ; Alayash, Abdu I. ; Manci, Elizabeth A. ; Belcher, John D. ; Vercellotti, Gregory M. / Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. In: British Journal of Haematology. 2016 ; Vol. 175, No. 4. pp. 714-723.
@article{6b30cb2e43ab4be3bc9347961b7d9d9c,
title = "Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function",
abstract = "There is growing evidence that extracellular haemoglobin and haem mediate inflammatory and oxidative damage in sickle cell disease. Haptoglobin (Hp), the scavenger for free haemoglobin, is depleted in most patients with sickle cell disease due to chronic haemolysis. Although single infusions of Hp can ameliorate vaso-occlusion in mouse models of sickle cell disease, prior studies have not examined the therapeutic benefits of more chronic Hp dosing on sickle cell disease manifestations. In the present study, we explored the effect of Hp treatment over a 3-month period in sickle mice at two dosing regimens: the first at a moderate dose of 200 mg/kg thrice weekly and the second at a higher dose of 400 mg/kg thrice weekly. We found that only the higher dosing regimen resulted in increased haem-oxygenase-1 and heavy chain ferritin (H-ferritin) expression and decreased iron deposition in the kidney. Despite the decreased kidney iron deposition following Hp treatment, there was no significant improvement in kidney function. However, there was a nearly significant trend towards decreased liver infarction.",
keywords = "H-ferritin, free haemoglobin, haem-oxygenase-1, haptoglobin, sickle cell disease",
author = "Shi, {Patricia A.} and Erika Choi and Chintagari, {Narendranath R.} and Julia Nguyen and Xinhua Guo and Karina Yazdanbakhsh and Narla Mohandas and Alayash, {Abdu I.} and Manci, {Elizabeth A.} and Belcher, {John D.} and Vercellotti, {Gregory M.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/bjh.14280",
language = "English (US)",
volume = "175",
pages = "714--723",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function

AU - Shi, Patricia A.

AU - Choi, Erika

AU - Chintagari, Narendranath R.

AU - Nguyen, Julia

AU - Guo, Xinhua

AU - Yazdanbakhsh, Karina

AU - Mohandas, Narla

AU - Alayash, Abdu I.

AU - Manci, Elizabeth A.

AU - Belcher, John D.

AU - Vercellotti, Gregory M.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - There is growing evidence that extracellular haemoglobin and haem mediate inflammatory and oxidative damage in sickle cell disease. Haptoglobin (Hp), the scavenger for free haemoglobin, is depleted in most patients with sickle cell disease due to chronic haemolysis. Although single infusions of Hp can ameliorate vaso-occlusion in mouse models of sickle cell disease, prior studies have not examined the therapeutic benefits of more chronic Hp dosing on sickle cell disease manifestations. In the present study, we explored the effect of Hp treatment over a 3-month period in sickle mice at two dosing regimens: the first at a moderate dose of 200 mg/kg thrice weekly and the second at a higher dose of 400 mg/kg thrice weekly. We found that only the higher dosing regimen resulted in increased haem-oxygenase-1 and heavy chain ferritin (H-ferritin) expression and decreased iron deposition in the kidney. Despite the decreased kidney iron deposition following Hp treatment, there was no significant improvement in kidney function. However, there was a nearly significant trend towards decreased liver infarction.

AB - There is growing evidence that extracellular haemoglobin and haem mediate inflammatory and oxidative damage in sickle cell disease. Haptoglobin (Hp), the scavenger for free haemoglobin, is depleted in most patients with sickle cell disease due to chronic haemolysis. Although single infusions of Hp can ameliorate vaso-occlusion in mouse models of sickle cell disease, prior studies have not examined the therapeutic benefits of more chronic Hp dosing on sickle cell disease manifestations. In the present study, we explored the effect of Hp treatment over a 3-month period in sickle mice at two dosing regimens: the first at a moderate dose of 200 mg/kg thrice weekly and the second at a higher dose of 400 mg/kg thrice weekly. We found that only the higher dosing regimen resulted in increased haem-oxygenase-1 and heavy chain ferritin (H-ferritin) expression and decreased iron deposition in the kidney. Despite the decreased kidney iron deposition following Hp treatment, there was no significant improvement in kidney function. However, there was a nearly significant trend towards decreased liver infarction.

KW - H-ferritin

KW - free haemoglobin

KW - haem-oxygenase-1

KW - haptoglobin

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84983000268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983000268&partnerID=8YFLogxK

U2 - 10.1111/bjh.14280

DO - 10.1111/bjh.14280

M3 - Article

VL - 175

SP - 714

EP - 723

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -